Next generation self-replicating RNA vectors for vaccines and immunotherapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5500
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Next generation self-replicating RNA vectors for vaccines and immunotherapies ; day:22 ; month:2 ; year:2022 ; pages:1-9
Cancer gene therapy ; (22.2.2022), 1-9
- Urheber
-
Aliahmad, Parinaz
Miyake-Stoner, Shigeki J.
Geall, Andrew J.
Wang, Nathaniel S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41417-022-00435-8
- URN
-
urn:nbn:de:101:1-2022102700143715149531
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aliahmad, Parinaz
- Miyake-Stoner, Shigeki J.
- Geall, Andrew J.
- Wang, Nathaniel S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches
Dual-vector prodrug activator gene therapy using retroviral replicating vectors
Rapid Transient Production in Plants by Replicating and Non-Replicating Vectors Yields High Quality Functional Anti-HIV Antibody
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Target discovery for T cell therapy: next steps to advance Immunotherapies
Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
DNA Replicons : next generation vaccines against allergy
P12-07. Novel HIV vaccines using chimeric influenza HA vectors
Cancer vaccines at an inflexion point: what next?
Immunotherapies in solid tumors
Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches
Dual-vector prodrug activator gene therapy using retroviral replicating vectors
Rapid Transient Production in Plants by Replicating and Non-Replicating Vectors Yields High Quality Functional Anti-HIV Antibody
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Target discovery for T cell therapy: next steps to advance Immunotherapies
Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
DNA Replicons : next generation vaccines against allergy
P12-07. Novel HIV vaccines using chimeric influenza HA vectors
Cancer vaccines at an inflexion point: what next?
Immunotherapies in solid tumors
Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches
Dual-vector prodrug activator gene therapy using retroviral replicating vectors
Rapid Transient Production in Plants by Replicating and Non-Replicating Vectors Yields High Quality Functional Anti-HIV Antibody
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Target discovery for T cell therapy: next steps to advance Immunotherapies
Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
DNA Replicons : next generation vaccines against allergy
P12-07. Novel HIV vaccines using chimeric influenza HA vectors
Cancer vaccines at an inflexion point: what next?